Loading…
Bharat Parenterals (BSE 541096)₹1,895+20.00%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Bharat Parenterals reported sales of ₹136 Cr, up 109.3% from Sep 2025, and net profit of ₹11.97 Cr. For the year to Mar 2026, sales were ₹344 Cr and net profit −₹26.93 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59.93 | 67.93 | 92.84 | 71.90 | 71.87 | 104 | 116 | 64.91 | 64.94 | 99.80 | 93.81 | 136 |
| Expenses | 53.12 | 67.17 | 88.25 | 79.29 | 69.19 | 102 | 102 | 64.15 | 63.21 | 100 | 85.19 | 113 |
| Operating Profit | 6.98 | 0.99 | 3.99 | −7.97 | 3.99 | 1.99 | 13.95 | 0.99 | 1.99 | −0.99 | 8.98 | 23.92 |
| OPM % | 11.0% | 1.5% | 4.8% | −11.0% | 5.0% | 2.1% | 12.0% | 1.3% | 2.7% | −0.5% | 9.0% | 17.1% |
| Other Income | 0.99 | 2.99 | 2.99 | 3.99 | 2.99 | 1.99 | 0.99 | 3.99 | 0.99 | 3.99 | 0.99 | 2.99 |
| Interest | 1.01 | 1.01 | 3.01 | 3.01 | 3.01 | 4.01 | 4.01 | 3.01 | 3.01 | 3.01 | 2.01 | 3.01 |
| Depreciation | 2.01 | 4.01 | 9.01 | 9.02 | 9.01 | 9.01 | 9.01 | 9.02 | 8.01 | 9.01 | 9.02 | 9.01 |
| Profit before tax | 4.99 | −0.99 | −4.99 | −14.98 | −5.99 | −7.98 | 2.99 | −6.99 | −7.99 | −7.99 | −1.99 | 13.98 |
| Tax % | 32.9% | 87.9% | 85.0% | 13.9% | 43.0% | 14.0% | 134.0% | 18.0% | 17.0% | −3.0% | 137.9% | 16.0% |
| Net Profit | 3.99 | −2.99 | −8.97 | −17.95 | −7.97 | −8.98 | −0.99 | −8.98 | −9.97 | −7.98 | −3.99 | 11.97 |
| EPS (Rs) | 6.51 | −0.51 | 1.97 | −11.51 | −2.43 | −6.87 | 11.95 | −10.51 | −6.38 | −6.97 | 1.48 | 13.68 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 261 | 340 | 344 | 394 |
| Expenses | 114 | 105 | 124 | 192 | 201 | 179 | 183 | 198 | 235 | 338 | 331 | 362 |
| Operating Profit | 9.97 | 6.97 | 11.97 | 28.92 | 27.91 | 24.93 | 28.91 | 19.92 | 26.89 | 3.98 | 15.95 | 33.90 |
| OPM % | 8.0% | 6.0% | 9.1% | 13.1% | 12.1% | 12.0% | 14.0% | 9.0% | 10.0% | 1.1% | 4.6% | 8.6% |
| Other Income | 4.98 | 7.99 | 6.99 | 12.97 | 10.98 | 8.98 | 6.99 | 11.98 | 4.99 | 10.97 | 9.98 | 8.96 |
| Interest | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 3.01 | 4.01 | 13.02 | 13.01 | 11.04 |
| Depreciation | 4.01 | 6.01 | 6.01 | 6.01 | 6.01 | 6.01 | 7.01 | 6.01 | 9.01 | 35.03 | 34.05 | 35.05 |
| Profit before tax | 8.98 | 6.99 | 12.97 | 34.92 | 32.95 | 26.94 | 27.95 | 23.97 | 18.96 | −33.92 | −20.97 | −3.99 |
| Tax % | 30.9% | 8.0% | 28.9% | 39.0% | 25.9% | 25.0% | 25.0% | 33.0% | 43.9% | 29.0% | 27.0% | — |
| Exceptional items | 0.02 | 0.00 | 0.00 | 0.02 | −0.30 | 0.23 | −0.54 | 0.30 | −0.06 | −0.70 | 0.30 | — |
| Net Profit | 5.99 | 6.98 | 8.98 | 20.95 | 23.95 | 19.94 | 20.94 | 15.95 | 10.98 | −43.89 | −26.93 | −9.97 |
| EPS (Rs) | 11.27 | 12.02 | 15.93 | 37.10 | 42.12 | 35.58 | 36.44 | 28.48 | 24.94 | −18.34 | −11.89 | 1.81 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.0% | 4.0% | −5.1% | −8.1% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.97 | 5.98 | 5.98 | 5.97 | 5.98 | 5.98 | 5.98 | 5.98 | 5.98 | 6.97 | 6.97 |
| Reserves | 50.88 | 57.93 | 66.93 | 87.81 | 112 | 138 | 160 | 177 | 191 | 324 | 314 |
| Borrowings | 18.94 | 5.99 | 8.98 | 4.99 | 0.99 | 11.97 | 17.95 | 49.93 | 158 | 180 | 146 |
| Other Liabilities | 43.79 | 39.81 | 49.75 | 59.72 | 67.67 | 42.79 | 41.80 | 117 | 148 | 137 | 144 |
| Total Liabilities | 120 | 110 | 132 | 158 | 188 | 199 | 225 | 350 | 503 | 648 | 611 |
| Fixed Assets | 34.90 | 30.94 | 33.93 | 34.93 | 32.94 | 44.90 | 40.89 | 41.88 | 211 | 251 | 254 |
| CWIP | 0.00 | 0.00 | 0.00 | 1.01 | 12.04 | 0.00 | 26.08 | 99.26 | 25.07 | 31.12 | 35.10 |
| Investments | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | 43.15 | 11.04 | 0.00 | 0.00 | 5.01 | 6.02 |
| Other Assets | 84.68 | 78.76 | 97.70 | 121 | 142 | 111 | 147 | 208 | 267 | 359 | 316 |
| Inventories | 14.03 | 15.02 | 14.02 | 23.06 | 29.07 | 22.04 | 21.05 | 38.10 | 61.10 | 72.20 | 85.12 |
| Trade receivables | 43.86 | 43.84 | 58.78 | 63.80 | 78.65 | 67.68 | 72.74 | 112 | 141 | 171 | 151 |
| Cash & equivalents | 12.98 | 1.99 | 3.99 | 11.97 | 9.98 | 1.99 | 4.99 | 9.98 | 14.96 | 57.84 | 11.97 |
| Total Assets | 120 | 110 | 132 | 158 | 188 | 199 | 225 | 350 | 503 | 648 | 611 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −1.99 | 5.98 | 19.93 | 13.97 | 23.92 | −0.99 | 21.94 | −4.99 | −26.90 | 37.89 |
| Cash from investing activity | −2.01 | −8.02 | −9.03 | −13.04 | −43.17 | −7.02 | −78.29 | −105 | −138 | 9.04 |
| Cash from financing activity | −8.03 | 4.01 | −4.02 | −3.01 | 10.03 | 9.03 | 61.19 | 110 | 156 | −47.17 |
| Net cash flow | −10.99 | 2.01 | 6.99 | −0.99 | −7.99 | 1.99 | 3.99 | 0.99 | −7.99 | 0.99 |
| Capex | 2.43 | 8.24 | 8.86 | 14.97 | 0.83 | 38.86 | 91.48 | 104 | 29.01 | 39.87 |
| Free cash flow | −3.99 | −1.99 | 11.99 | 0.00 | 23.99 | −39.97 | −67.95 | −108 | −55.96 | −0.99 |
| CFO / OP % | −8.0% | 72.9% | 106.9% | 86.9% | 123.0% | 16.0% | 150.0% | 17.9% | −444.1% | 304.9% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 198 | 184 | 159 |
| Inventory days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 132 | 162 |
| Days payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 137 | 136 | 122 |
| Cash conversion cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 152 | 202 | 180 | 199 |
| Working capital days | 8 | 64 | 78 | 73 | 89 | 106 | 148 | 91 | 81 | 76 | 143 |
| ROCE % | — | 11.0% | 18.0% | 38.9% | 31.0% | 19.9% | 17.0% | 10.9% | 7.0% | −4.0% | −2.0% |
For the Sep 2026 quarter, Bharat Parenterals reported sales of ₹136 Cr, up 109.3% year on year and net profit of ₹11.97 Cr. The operating margin was 17.1%.
Bharat Parenterals' sales for the year to Mar 2026 were ₹344 Cr; over the last twelve months they were ₹394 Cr.
Net profit for the year to Mar 2026 was −₹26.93 Cr, and −₹9.97 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.81.
Bharat Parenterals reported borrowings of ₹146 Cr at Mar 2026, against cash and equivalents of ₹11.97 Cr.
Cash from operations was ₹37.89 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.